Literature DB >> 20542464

VZV meningitis following varicella vaccine.

Dahlene Fusco1, Peter Krawitz, Philip LaRussa, Sharon Steinberg, Anne Gershon, Jonathan Jacobs.   

Abstract

Live attenuated varicella zoster virus is administered to prevent varicella in children and herpes zoster in the elderly. We report a case of disseminated herpes zoster in a previously healthy elderly woman hours after Oka strain vaccination. PCR and restriction enzyme analysis revealed that symptoms were caused by wild type virus. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20542464      PMCID： PMC5391039          DOI： 10.1016/j.jcv.2010.04.014

Source DB:  PubMed          Journal:  J Clin Virol        ISSN： 1386-6532            Impact factor:   3.168


  10 in total

1.  Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection?

Authors:  P Cinque; S Bossolasco; L Vago; C Fornara; S Lipari; S Racca; A Lazzarin; A Linde
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

2.  Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.

Authors:  E Trannoy; R Berger; G Holländer; F Bailleux; P Heimendinger; D Vuillier; H Creusvaux
Journal:  Vaccine       Date:  2000-02-25       Impact factor: 3.641

Review 3.  Herpes zoster in older adults.

Authors:  K Schmader
Journal:  Clin Infect Dis       Date:  2001-04-17       Impact factor: 9.079

4.  Immune responses to varicella-zoster in the aged.

Authors:  B L Burke; R W Steele; O W Beard; J S Wood; T D Cain; D J Marmer
Journal:  Arch Intern Med       Date:  1982-02

5.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Authors:  M N Oxman; M J Levin; G R Johnson; K E Schmader; S E Straus; L D Gelb; R D Arbeit; M S Simberkoff; A A Gershon; L E Davis; A Weinberg; K D Boardman; H M Williams; J Hongyuan Zhang; P N Peduzzi; C E Beisel; V A Morrison; J C Guatelli; P A Brooks; C A Kauffman; C T Pachucki; K M Neuzil; R F Betts; P F Wright; M R Griffin; P Brunell; N E Soto; A R Marques; S K Keay; R P Goodman; D J Cotton; J W Gnann; J Loutit; M Holodniy; W A Keitel; G E Crawford; S-S Yeh; Z Lobo; J F Toney; R N Greenberg; P M Keller; R Harbecke; A R Hayward; M R Irwin; T C Kyriakides; C Y Chan; I S F Chan; W W B Wang; P W Annunziato; J L Silber
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

6.  Genotyping of varicella-zoster virus and the discrimination of Oka vaccine strains by TaqMan real-time PCR.

Authors:  S P Parker; M Quinlivan; Y Taha; J Breuer
Journal:  J Clin Microbiol       Date:  2006-11       Impact factor: 5.948

7.  Live attenuated varicella virus vaccine. Efficacy trial in healthy children.

Authors:  R E Weibel; B J Neff; B J Kuter; H A Guess; C A Rothenberger; A J Fitzgerald; K A Connor; A A McLean; M R Hilleman; E B Buynak
Journal:  N Engl J Med       Date:  1984-05-31       Impact factor: 91.245

8.  A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older.

Authors:  R Berger; E Trannoy; G Holländer; F Bailleux; C Rudin; H Creusvaux
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

9.  Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates.

Authors:  P LaRussa; O Lungu; I Hardy; A Gershon; S P Steinberg; S Silverstein
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  Lack of association between measles virus vaccine and autism with enteropathy: a case-control study.

Authors:  Mady Hornig; Thomas Briese; Timothy Buie; Margaret L Bauman; Gregory Lauwers; Ulrike Siemetzki; Kimberly Hummel; Paul A Rota; William J Bellini; John J O'Leary; Orla Sheils; Errol Alden; Larry Pickering; W Ian Lipkin
Journal:  PLoS One       Date:  2008-09-04       Impact factor: 3.240
  10 in total
  2 in total

Review 1.  Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data.

Authors:  G S Goldman; P G King
Journal:  Vaccine       Date:  2012-06-01       Impact factor: 3.641

Review 2.  Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.